Tumour vascular targeting

It is now accepted that the growth of solid tumours is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process. More recently, it has become apparent that targeted destruction of the established tumour vasculature is another avenue for exciting therapeutic opportunities. In this article, we present evidence that vascular targeting is an effective antitumour strategy in animal models, describe strategies for identifying putative tumour vascular targets and discuss future prospects for vascular targeting in the clinic.

[1]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  K. Wüthrich,et al.  NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. , 1999, Structure.

[3]  W. Woglom A Critique of Tumor Resistance , 1922 .

[4]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Maio,et al.  Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[7]  Dario Neri,et al.  In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature , 2005, Nature Methods.

[8]  C. Sheehan,et al.  Prognostic factors in prostate cancer. , 2003, American journal of clinical pathology.

[9]  H. Dvorak,et al.  Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. , 1996, European journal of cancer.

[10]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[11]  P. Janmey,et al.  Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide. , 2001, Biochemistry.

[12]  L. Zardi,et al.  Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. , 2001, Nucleic acids research.

[13]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[14]  Borivoj Vojnovic,et al.  Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. , 2005, Advanced drug delivery reviews.

[15]  P. Carmeliet Angiogenesis in health and disease , 2003, Nature Medicine.

[16]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[17]  Lukasz Huminiecki,et al.  In Silico Cloning of Novel Endothelial-Specific Genes , 2000 .

[18]  Dario Neri,et al.  Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin , 2001, European Journal of Nuclear Medicine.

[19]  D. Neri,et al.  Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. , 2004, Biochemistry.

[20]  J. Denekamp,et al.  Endothelial-cell proliferation in experimental tumours. , 1982, British Journal of Cancer.

[21]  D. Neri,et al.  Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study , 2004, Proteomics.

[22]  R. Begent,et al.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C , 2004 .

[23]  G. Viale,et al.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. , 1999, The American journal of pathology.

[24]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[25]  B. Hogan,et al.  Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor , 1997 .

[26]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[27]  D. Vestweber,et al.  Biochemical Characterization and Molecular Cloning of a Novel Endothelial-Specific Sialomucin , 1999 .

[28]  R. Schwendener,et al.  Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes , 2002, British Journal of Cancer.

[29]  W. Richards,et al.  Dll4, a novel Notch ligand expressed in arterial endothelium. , 2000, Genes & development.

[30]  A. Pini,et al.  Design and Use of a Phage Display Library , 1998, The Journal of Biological Chemistry.

[31]  W. Stanford,et al.  Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. , 1998, Blood.

[32]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.

[33]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[34]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[35]  A. Pini,et al.  Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain , 1996, International journal of cancer.

[36]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[37]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[38]  L. Zardi,et al.  Lack of specificity of endoglin expression for tumor blood vessels , 2001, International journal of cancer.

[39]  S. Ran,et al.  Increased exposure of anionic phospholipids on the surface of tumor blood vessels. , 2002, Cancer research.

[40]  H. Kosmehl,et al.  mRNA expression and protein distribution of the unspliced tenascin‐C isoform in prostatic adenocarcinoma , 2004, The Journal of pathology.

[41]  F. Eisenhaber,et al.  Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium* , 2001, The Journal of Biological Chemistry.

[42]  David R. Liu,et al.  DNA-Templated Organic Synthesis and Selection of a Library of Macrocycles , 2004, Science.

[43]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[44]  Michael Streit,et al.  Angiogenesis, lymphangiogenesis, and melanoma metastasis , 2003, Oncogene.

[45]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[46]  C. Halin,et al.  Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins , 2002, International journal of cancer.

[47]  D. Spencer,et al.  A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.

[48]  Michael Gorn,et al.  Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. , 2002, Genomics.

[49]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[50]  K. Alitalo,et al.  Role of lymphangiogenic factors in tumor metastasis. , 2004, Biochimica et biophysica acta.

[51]  Angelo Corti,et al.  Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.

[52]  C. Isacke,et al.  Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium , 2005, FEBS letters.

[53]  Iris Verel,et al.  Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head‐and‐neck cancer xenografts , 2002, International journal of cancer.

[54]  N. Bander,et al.  In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.

[55]  Franklin Peale,et al.  In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.

[56]  Carlo Giussani,et al.  Combinatorial Administration of Molecules That Simultaneously Inhibit Angiogenesis and Invasion Leads to Increased Therapeutic Efficacy in Mouse Models of Malignant Glioma , 2004, Clinical Cancer Research.

[57]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  K. Sekiguchi,et al.  Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. , 2002, Cancer research.

[59]  G. Giuliani,et al.  Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[61]  M E Hammond,et al.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[62]  R. Barrett,et al.  Increased potency of an erythropoietin peptide mimetic through covalent dimerization , 1997, Nature Biotechnology.

[63]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[64]  Christopher A. Jones,et al.  Robo4 is a vascular-specific receptor that inhibits endothelial migration. , 2003, Developmental biology.

[65]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[66]  W. Oyen,et al.  Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  E. Livingston,et al.  Human endomucin is an endothelial marker. , 2001, Biochemical and biophysical research communications.

[68]  C. Halin,et al.  Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. , 2002, Bioconjugate chemistry.

[69]  J. Yodoi,et al.  Persistent oxidative stress in cancer , 1995, FEBS letters.

[70]  F. Baralle,et al.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. , 1987, The EMBO journal.

[71]  F. Peale,et al.  Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.

[72]  T. Waldmann,et al.  Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At , 2002, Radiation research.

[73]  Y. Collan,et al.  Prognostic factors in prostate cancer , 2006, Diagnostic pathology.

[74]  S. Hauptmann,et al.  Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[75]  D. McDonald,et al.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.

[76]  W. Oyen,et al.  Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .

[77]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[78]  M. Tschöp,et al.  Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Mulligan,et al.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Clemencia Pinilla,et al.  Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries , 2003, Nature Medicine.

[81]  P. Rao,et al.  Isolation and characterization of the notch ligand delta4. , 2000, Experimental cell research.

[82]  J. Szostak,et al.  Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures , 1992, Nature.

[83]  M. S. Clarke,et al.  The identification of proliferation and tumour‐induced proteins in human endothelial cells: A possible target for tumour therapy , 1991, Electrophoresis.

[84]  B. Teicher,et al.  Murine Endothelial Cell Lines as Models of Tumor Endothelial Cells , 2004, Clinical Cancer Research.

[85]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[86]  N. Tommerup,et al.  Molecular Characterization of a Novel Human Hybrid-type Receptor That Binds the α2-Macroglobulin Receptor-associated Protein* , 1996, The Journal of Biological Chemistry.

[87]  B. St. Croix,et al.  Tumor endothelial markers: new targets for cancer therapy , 2004, Current opinion in oncology.

[88]  C. Halin,et al.  An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. , 2002, International journal of radiation oncology, biology, physics.

[89]  William R Wagner,et al.  Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. , 2005, Cancer research.

[90]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[91]  Dario Neri,et al.  Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment , 1999, Nature Biotechnology.

[92]  Olof Ramström,et al.  Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.

[93]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[94]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[95]  L. Zardi,et al.  Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1994, International journal of cancer.

[96]  Y. Tsutsumi,et al.  Effective Cancer Targeting Using an Anti‐tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES‐23) , 2000, Japanese journal of cancer research : Gann.

[97]  Zhen-ping Zhu,et al.  Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor , 2004, Investigational New Drugs.

[98]  C. Halin,et al.  Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. , 1999, Journal of immunological methods.

[99]  R. Frank The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. , 2002, Journal of immunological methods.

[100]  D. Hicklin,et al.  Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis , 2002, The Journal of experimental medicine.

[101]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[102]  Daniel S. Miller,et al.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[103]  Marc Dellian,et al.  Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  Didier Y. R. Stainier,et al.  The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation , 2004, Nature.

[105]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[106]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[107]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[108]  L. Zardi,et al.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.

[109]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[110]  L. Dinkelborg,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels , 1999 .

[111]  C. Halin,et al.  Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.

[112]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[113]  G. Viale,et al.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. , 2002, The American journal of pathology.

[114]  J. Bowsher,et al.  Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. , 2004, Blood.

[115]  J. Rossant,et al.  Gene-trap expression screening to identify endothelial-specific genes. , 2004, Blood.

[116]  A. Michalowski,et al.  The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. , 1990, British Journal of Cancer.

[117]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[118]  K. Kinzler,et al.  Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.

[119]  G. V. Vande Woude,et al.  Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Dario Neri,et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  F. Peale,et al.  Stanniocalcin 1 Is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor* , 2003, Journal of Biological Chemistry.

[122]  K. terBrugge,et al.  Analysis of Endoglin Expression in Normal Brain Tissue and in Cerebral Arteriovenous Malformations , 2000, Stroke.

[123]  F. Felici,et al.  Peptide and protein display on the surface of filamentous bacteriophage. , 1995, Biotechnology annual review.

[124]  R Bicknell,et al.  Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.

[125]  S. Stoeckli,et al.  Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors , 2003, The Laryngoscope.

[126]  K. Kairemo,et al.  131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study. , 1999, Acta oncologica.

[127]  L. Zardi,et al.  The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. , 1992, The Journal of biological chemistry.

[128]  R. Falchetto,et al.  SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. , 2004, Analytical biochemistry.

[129]  L. Zardi,et al.  Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.

[130]  George Matcuk,et al.  Identification of endothelial cell genes by combined database mining and microarray analysis. , 2003, Physiological genomics.

[131]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[132]  Steffen Helmling,et al.  RNAスピーゲルマーによるグレリン活性のin vitro及びin vivo阻害 , 2004 .

[133]  Yan Li,et al.  Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis , 2003, Molecular and Cellular Biology.

[134]  R. Xiang,et al.  DNA vaccines suppress tumor growth and metastases by the induction of anti‐angiogenesis , 2004, Immunological reviews.

[135]  F. D. De Braud,et al.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.

[136]  S. Vallabhajosula,et al.  Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  R. Poulsom,et al.  EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor* , 2003, Journal of Biological Chemistry.

[138]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[139]  A. Plückthun,et al.  Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. , 1999, Journal of immunological methods.

[140]  L. Zardi,et al.  The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.

[141]  M A Konerding,et al.  3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon , 2001, British Journal of Cancer.

[142]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[143]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[144]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[145]  H. Kosmehl,et al.  This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels , 2022 .

[146]  I Fisch,et al.  "Peptabody": a new type of high avidity binding protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[147]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[148]  H. Kosmehl,et al.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. , 2002, Blood.

[149]  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[150]  F. Burrows,et al.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[152]  J. Denekamp Vascular attack as a therapeutic strategy for cancer , 1990, Cancer and Metastasis Reviews.

[153]  R. Fleischmann,et al.  Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. , 1995, Nature.

[154]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[156]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[157]  R. Hynes,et al.  Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. , 1996, Cell adhesion and communication.

[158]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[159]  R. Hynes,et al.  Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. , 1996, Cell adhesion and communication.

[160]  David E. Gloriam,et al.  The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. , 2004, Genomics.

[161]  J. Wadenbäck,et al.  Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. , 2001, Journal of biotechnology.